73 related articles for article (PubMed ID: 23660393)
1. Reply: lung toxicity of hydroxyl-β-cyclodextrin infusion.
Matsuo M; Arima H; Irie T
Mol Genet Metab; 2013 Jun; 109(2):233. PubMed ID: 23660393
[No Abstract] [Full Text] [Related]
2. Lung toxicity of hydroxypropyl-β-cyclodextrin infusion.
Chien YH; Shieh YD; Yang CY; Lee NC; Hwu WL
Mol Genet Metab; 2013 Jun; 109(2):231-2. PubMed ID: 23611577
[No Abstract] [Full Text] [Related]
3. [Treatment with cyclodextrin for Niemann Pick s disease].
Cruz-Pardos S; García-Poza P; Sánchez-García FJ
Farm Hosp; 2013; 37(3):271-2. PubMed ID: 23789807
[No Abstract] [Full Text] [Related]
4. Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients.
García-Robles AA; Company-Albir MJ; Megías-Vericat JE; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Alcalá-Vicente C; Galeano I; Casanova B; Poveda JL
J Neurol Sci; 2016 Jul; 366():65-67. PubMed ID: 27288778
[No Abstract] [Full Text] [Related]
5. Methyl-β-cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK.
Dai S; Dulcey AE; Hu X; Wassif CA; Porter FD; Austin CP; Ory DS; Marugan J; Zheng W
Autophagy; 2017 Aug; 13(8):1435-1451. PubMed ID: 28613987
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1.
Maarup TJ; Chen AH; Porter FD; Farhat NY; Ory DS; Sidhu R; Jiang X; Dickson PI
Mol Genet Metab; 2015; 116(1-2):75-9. PubMed ID: 26189084
[TBL] [Abstract][Full Text] [Related]
7. Response letter to comments on "Cyclodextrins promote protein aggregation posing risks for therapeutic applications".
Wang M; Boddapati S; Sierks M
Biochem Biophys Res Commun; 2009 Dec; 390(4):1426-7. PubMed ID: 19852940
[No Abstract] [Full Text] [Related]
8. Effects of cyclodextrin in two patients with Niemann-Pick Type C disease.
Matsuo M; Togawa M; Hirabaru K; Mochinaga S; Narita A; Adachi M; Egashira M; Irie T; Ohno K
Mol Genet Metab; 2013 Jan; 108(1):76-81. PubMed ID: 23218948
[TBL] [Abstract][Full Text] [Related]
9. Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1.
Yergey AL; Blank PS; Cologna SM; Backlund PS; Porter FD; Darling AJ
PLoS One; 2017; 12(4):e0175478. PubMed ID: 28414792
[TBL] [Abstract][Full Text] [Related]
10. [Report of attendance at the Parseghian Scientific Conference for Niemann-Pick Type C (NP-C) Research, South Bend, Indiana: in search of new therapeutic possibilities for a very rare illness].
Fornfeist S
Kinderkrankenschwester; 2011 Oct; 30(10):425-7. PubMed ID: 22029143
[No Abstract] [Full Text] [Related]
11. Cyclodextrins, blood-brain barrier, and treatment of neurological diseases.
Vecsernyés M; Fenyvesi F; Bácskay I; Deli MA; Szente L; Fenyvesi É
Arch Med Res; 2014 Nov; 45(8):711-29. PubMed ID: 25482528
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease.
Tanaka Y; Yamada Y; Ishitsuka Y; Matsuo M; Shiraishi K; Wada K; Uchio Y; Kondo Y; Takeo T; Nakagata N; Higashi T; Motoyama K; Arima H; Mochinaga S; Higaki K; Ohno K; Irie T
Biol Pharm Bull; 2015; 38(6):844-51. PubMed ID: 26027824
[TBL] [Abstract][Full Text] [Related]
13. Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells.
Rosenbaum AI; Zhang G; Warren JD; Maxfield FR
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5477-82. PubMed ID: 20212119
[TBL] [Abstract][Full Text] [Related]
14. HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells.
Soga M; Ishitsuka Y; Hamasaki M; Yoneda K; Furuya H; Matsuo M; Ihn H; Fusaki N; Nakamura K; Nakagata N; Endo F; Irie T; Era T
Stem Cells; 2015 Apr; 33(4):1075-88. PubMed ID: 25522247
[TBL] [Abstract][Full Text] [Related]
15. Neurometabolic disease: New drug slows Niemann-Pick disease.
Ridler C
Nat Rev Neurol; 2017 Oct; 13(10):576-577. PubMed ID: 28849784
[No Abstract] [Full Text] [Related]
16. Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases.
Megías-Vericat JE; García-Robles A; Company-Albir MJ; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Casanova B; Poveda JL
Neurol Sci; 2017 May; 38(5):727-743. PubMed ID: 28155026
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of direct delivery of hydroxypropyl-beta-cyclodextrin to the lung by the nasal route in a mouse model of Niemann-Pick C1 disease: motor performance is unaltered and lung disease is worsened.
Erickson RP; Deutsch G; Patil R
J Appl Genet; 2018 May; 59(2):187-191. PubMed ID: 29411332
[TBL] [Abstract][Full Text] [Related]
18. Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.
Alam MS; Getz M; Haldar K
Sci Transl Med; 2016 Feb; 8(326):326ra23. PubMed ID: 26888431
[TBL] [Abstract][Full Text] [Related]
19. Application of a simple methodology to analyze Hydroxypropyl-β-Cyclodextrin in urine using HPLC-LS in early Niemann-Pick disease type C patient.
Matencio A; Alcaráz-Gómez MA; García-Carmona F; Arias B; López-Nicolás JM
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Sep; 1093-1094():47-51. PubMed ID: 29990712
[TBL] [Abstract][Full Text] [Related]
20. [Niemann-Pick type C disease: an early diagnosis for a therapeutic hope].
Ogier de Baulny H
Arch Pediatr; 2010 Jun; 17 Suppl 2():S39-40. PubMed ID: 20620893
[No Abstract] [Full Text] [Related]
[Next] [New Search]
